Dealbreaker on MSN
Liquid biopsy firm Freenome finds a way to the public markets via $330M SPAC merger
Freenome’s SPAC merger agreement comes as the liquid biopsy developer prepares for potential 2026 commercialization of SimpleScreen, a colorectal cancer test currently under FDA review.
Fintel reports that on December 11, 2025, Citigroup maintained coverage of Guardant Health (NasdaqGS:GH) with a Buy recommendation. Analyst Price Forecast Suggests 0.65% Downside As of December 6, ...
As of December 6, 2025, the average one-year price target for Guardant Health is $100.72/share. The forecasts range from a low of $48.69 to a high of $136.50. The average price target represents a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback